Ahead of the July 17 advisory committee meeting, the FDA raised concerns about the ocular toxicity profile and dose optimization of GSK's antibody-drug conjugate Blenrep for relapsed or refractory multiple myeloma. While previous trials showed efficacy, the high rate of severe eye-related adverse events and dose modifications have made the benefit-risk balance unclear. The drug was voluntarily withdrawn in 2022 after confirmatory trial failures but is being considered for market re-entry with revised dosing regimens.